Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDMD NASDAQ:CLPT NASDAQ:DRTS NASDAQ:NPCE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDMDBaird Medical Investment$2.60+6.1%$2.51$1.05▼$12.50$92.90M-0.98320,903 shs417,185 shsCLPTClearPoint Neuro$10.47-0.2%$10.95$9.76▼$19.22$297.66M0.89313,934 shs343,651 shsDRTSAlpha Tau Medical$3.85+1.0%$3.26$2.11▼$4.39$326.56M163,822 shs40,888 shsNPCENeuroPace$9.82-0.4%$9.20$5.45▼$18.98$324.85M1.9266,833 shs122,052 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDMDBaird Medical Investment0.00%+6.06%+7.46%-56.33%+244,999,900.00%CLPTClearPoint Neuro0.00%-5.07%-9.18%-9.57%-16.68%DRTSAlpha Tau Medical0.00%+5.83%+16.16%+27.00%+62.82%NPCENeuroPace0.00%+1.34%+15.19%-11.09%+32.71%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDMDBaird Medical Investment$2.60+6.1%$2.51$1.05▼$12.50$92.90M-0.98320,903 shs417,185 shsCLPTClearPoint Neuro$10.47-0.2%$10.95$9.76▼$19.22$297.66M0.89313,934 shs343,651 shsDRTSAlpha Tau Medical$3.85+1.0%$3.26$2.11▼$4.39$326.56M163,822 shs40,888 shsNPCENeuroPace$9.82-0.4%$9.20$5.45▼$18.98$324.85M1.9266,833 shs122,052 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDMDBaird Medical Investment0.00%+6.06%+7.46%-56.33%+244,999,900.00%CLPTClearPoint Neuro0.00%-5.07%-9.18%-9.57%-16.68%DRTSAlpha Tau Medical0.00%+5.83%+16.16%+27.00%+62.82%NPCENeuroPace0.00%+1.34%+15.19%-11.09%+32.71%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDMDBaird Medical Investment 0.00N/AN/AN/ACLPTClearPoint Neuro 3.00Buy$19.6787.84% UpsideDRTSAlpha Tau Medical 3.00Buy$9.00133.77% UpsideNPCENeuroPace 2.83Moderate Buy$16.6069.04% UpsideCurrent Analyst Ratings BreakdownLatest BDMD, DRTS, NPCE, and CLPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025DRTSAlpha Tau MedicalHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.008/13/2025NPCENeuroPaceZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/13/2025NPCENeuroPaceWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$17.00 ➝ $15.008/1/2025CLPTClearPoint NeuroStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.00 ➝ $9.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDMDBaird Medical InvestmentN/AN/AN/AN/AN/AN/ACLPTClearPoint Neuro$31.39M9.48N/AN/A$0.92 per share11.38DRTSAlpha Tau MedicalN/AN/AN/AN/A$0.89 per shareN/ANPCENeuroPace$79.91M4.07N/AN/A$0.27 per share36.37Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDMDBaird Medical InvestmentN/AN/A0.00∞N/AN/AN/AN/AN/ACLPTClearPoint Neuro-$18.91M-$0.81N/AN/AN/A-66.15%-94.44%-51.58%11/6/2025 (Estimated)DRTSAlpha Tau Medical-$31.75M-$0.48N/AN/AN/AN/A-51.21%-38.18%11/18/2025 (Estimated)NPCENeuroPace-$27.14M-$0.84N/AN/AN/A-29.29%-168.61%-25.48%11/11/2025 (Estimated)Latest BDMD, DRTS, NPCE, and CLPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025CLPTClearPoint Neuro-$0.20-$0.21-$0.01-$0.21$9.20 million$9.22 million8/12/2025Q2 2025NPCENeuroPace-$0.24-$0.26-$0.02-$0.26$23.08 million$23.52 million8/11/2025Q2 2025DRTSAlpha Tau Medical-$0.12-$0.13-$0.01-$0.13N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBDMDBaird Medical InvestmentN/AN/AN/AN/AN/ACLPTClearPoint NeuroN/AN/AN/AN/AN/ADRTSAlpha Tau MedicalN/AN/AN/AN/AN/ANPCENeuroPaceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDMDBaird Medical InvestmentN/AN/AN/ACLPTClearPoint Neuro1.467.306.45DRTSAlpha Tau Medical0.0710.525.81NPCENeuroPace3.025.474.51Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDMDBaird Medical Investment19.78%CLPTClearPoint Neuro30.08%DRTSAlpha Tau Medical2.65%NPCENeuroPace78.83%Insider OwnershipCompanyInsider OwnershipBDMDBaird Medical Investment78.90%CLPTClearPoint Neuro6.11%DRTSAlpha Tau Medical39.50%NPCENeuroPace20.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDMDBaird Medical InvestmentN/A35.73 million7.54 millionN/ACLPTClearPoint Neuro11028.43 million26.69 millionOptionableDRTSAlpha Tau Medical8084.82 million51.32 millionNo DataNPCENeuroPace17033.08 million26.30 millionOptionableBDMD, DRTS, NPCE, and CLPT HeadlinesRecent News About These CompaniesNeuroPace, Inc. (NASDAQ:NPCE) Given Average Rating of "Moderate Buy" by AnalystsSeptember 15 at 4:22 AM | marketbeat.comNeuroPace, Inc.'s (NASDAQ:NPCE) Intrinsic Value Is Potentially 99% Above Its Share PriceSeptember 10, 2025 | uk.finance.yahoo.comFirst Light Asset Management LLC Takes Position in NeuroPace, Inc. $NPCESeptember 4, 2025 | marketbeat.comNantahala Capital Management LLC Lowers Stake in NeuroPace, Inc. $NPCESeptember 3, 2025 | marketbeat.comGhisallo Capital Management LLC Buys Shares of 200,000 NeuroPace, Inc. $NPCESeptember 2, 2025 | marketbeat.comArmistice Capital LLC Purchases 561,000 Shares of NeuroPace, Inc. $NPCESeptember 2, 2025 | marketbeat.comDriehaus Capital Management LLC Purchases Shares of 803,440 NeuroPace, Inc. $NPCESeptember 2, 2025 | marketbeat.comRussell Investments Group Ltd. Takes $552,000 Position in NeuroPace, Inc. $NPCESeptember 2, 2025 | marketbeat.comWalleye Capital LLC Boosts Stock Position in NeuroPace, Inc. $NPCESeptember 1, 2025 | marketbeat.comNeuroPace, Inc. Reports Record Revenue and Strong Margins in Q2 2025 Earnings CallAugust 31, 2025 | tipranks.comNeuroPace to Participate in Upcoming Healthcare ConferencesAugust 28, 2025 | businesswire.comNeuroPace, Inc. (NASDAQ:NPCE) Given Average Recommendation of "Moderate Buy" by BrokeragesAugust 21, 2025 | marketbeat.com466,015 Shares in NeuroPace, Inc. (NASDAQ:NPCE) Acquired by Lord Abbett & CO. LLCAugust 19, 2025 | marketbeat.comQ3 Earnings Estimate for NeuroPace Issued By HC WainwrightAugust 19, 2025 | marketbeat.comQ1 Earnings Forecast for NeuroPace Issued By HC WainwrightAugust 17, 2025 | marketbeat.comCantor Fitzgerald Lifts Earnings Estimates for NeuroPaceAugust 17, 2025 | marketbeat.comFY2025 EPS Forecast for NeuroPace Increased by AnalystAugust 17, 2025 | marketbeat.comNeuroPace FY2029 EPS Estimate Boosted by Leerink PartnrsAugust 16, 2025 | marketbeat.comDeutsche Bank AG Grows Position in NeuroPace, Inc. (NASDAQ:NPCE)August 16, 2025 | marketbeat.comWells Fargo & Company Has Lowered Expectations for NeuroPace (NASDAQ:NPCE) Stock PriceAugust 15, 2025 | marketbeat.comNeuroPace, Inc. (NASDAQ:NPCE) Q2 2025 Earnings Call TranscriptAugust 13, 2025 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBDMD, DRTS, NPCE, and CLPT Company DescriptionsBaird Medical Investment NASDAQ:BDMD$2.60 +0.15 (+6.12%) As of 04:00 PM EasternBaird Medical Investment Holdings Ltd. is a medical technology company, which engages in the development and provision of medical devices. It is also involved in the design, development, manufacturing, and sale of microwave ablation medical devices, as well as sale of other medical devices. The company was founded on June 16, 2023 and is headquartered in Guangzhou, China.ClearPoint Neuro NASDAQ:CLPT$10.47 -0.02 (-0.19%) Closing price 04:00 PM EasternExtended Trading$10.73 +0.26 (+2.48%) As of 04:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.Alpha Tau Medical NASDAQ:DRTS$3.85 +0.04 (+1.05%) Closing price 03:59 PM EasternExtended Trading$3.85 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.NeuroPace NASDAQ:NPCE$9.82 -0.04 (-0.41%) Closing price 04:00 PM EasternExtended Trading$9.82 -0.01 (-0.05%) As of 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Royal Caribbean's 33% Dividend Hike Signals Deeper Growth MarketBeat Week in Review – 09/08 - 09/12 Adobe’s Rebound Has Room to Run: 25% Upside by Year-End Wall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
